Target Validation Information
Target ID T62276
Target Name NMDA receptor subunit NR1
Target Type
Clinical Trial
Drug Potency against Target 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one Drug Info IC50 = 4500 nM
4,6-Dichloro-1H-indole-2-carboxylic acid Drug Info IC50 = 6000 nM [1]
RPR-118723 Drug Info IC50 = 28 nM [2]
4-Phosphonomethyl-piperidine-2-carboxylic acid Drug Info IC50 = 452 nM [3]
GLUTAMATE Drug Info IC50 = 70 nM [4]
4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one Drug Info Ki = 16400 nM [5]
Gly-Hyp-Glu Drug Info Ki = 9240 nM [6]
H-Gly-PMe-Glu-OH Drug Info Ki = 7960 nM [7]
H-Gly-D-dmP-Glu-OH Drug Info Ki = 330 nM [7]
N,N'-Bis-(4-isopropyl-phenyl)-guanidine Drug Info IC50 = 17900 nM [8]
N,N'-Bis-(4-butyl-phenyl)-guanidine Drug Info IC50 = 3320 nM [8]
N,N'-Bis-(4-sec-butyl-phenyl)-guanidine Drug Info IC50 = 10100 nM [8]
N,N'-Bis-(4-butoxy-phenyl)-guanidine Drug Info IC50 = 3480 nM [8]
DITOLYLGUANIDINE Drug Info IC50 = 10200 nM [8]
6-Nitro-1,4-dihydro-quinoxaline-2,3-dione Drug Info IC50 = 3800 nM [9]
4-[2-(4-Phenyl-butoxy)-ethyl]-phenol Drug Info IC50 = 3700 nM [10]
3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 12000 nM [11]
3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 13000 nM [11]
3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 130 nM [11]
3-phenyl-4-hydroxyquinolin-2(1H)-one Drug Info Ki = 12200 nM [5]
5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one Drug Info IC50 = 97 nM
2-Methylamino-succinic acid(NMDA) Drug Info IC50 = 6000 nM [12]
5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Drug Info IC50 = 750 nM [13]
MDL-105519 Drug Info IC50 = 157 nM [14]
4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one Drug Info IC50 = 2800 nM
L-695902 Drug Info IC50 = 6500 nM
(R)-2-Amino-5-phosphono-pentanoic acid Drug Info Ki = 2260 nM [15]
3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid Drug Info IC50 = 810 nM
N-(2-methoxybenzyl)cinnamamidine Drug Info IC50 = 6.6 nM [16]
2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol Drug Info Ki = 140 nM [17]
DIZOCILPINE Drug Info Ki = 2.2 nM [18]
5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione Drug Info IC50 = 30 nM
RPR-104632 Drug Info IC50 = 8.3 nM [2]
6-Chloro-1,4-dihydro-quinoxaline-2,3-dione Drug Info IC50 = 1800 nM [9]
6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione Drug Info IC50 = 130 nM
YM-90K Drug Info IC50 = 10400 nM [19]
7-chloro-3-hydroxyquinazoline-2,4-dione Drug Info Ki = 240 nM [20]
Besonprodil Drug Info IC50 = 6.6 nM [21]
L-701324 Drug Info Ki = 1.4 nM [5]
Gly-Pip-Glu Drug Info Ki = 2390 nM [6]
Phe-Pro-Glu Drug Info Ki = 4850 nM [6]
Phenethyl-(4-phenyl-butyl)-amine Drug Info IC50 = 3500 nM [10]
(R)-2-Amino-7-phosphono-heptanoic acid Drug Info Ki = 2660 nM [15]
N,N'-Bis-(4-ethyl-phenyl)-guanidine Drug Info IC50 = 7910 nM [8]
2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline Drug Info Ki = 8 nM [22]
4-Benzyl-1-(2-phenoxy-ethyl)-piperidine Drug Info IC50 = 630 nM [23]
2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine Drug Info Ki = 180 nM [17]
8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 490 nM [11]
8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 5100 nM [11]
2-(4-Phenoxy-benzyl)-1H-benzoimidazole Drug Info Ki = 260 nM [17]
4-[3-(5-Phenyl-pentylamino)-propyl]-phenol Drug Info IC50 = 45 nM [10]
TRANSTORINE Drug Info IC50 = 16000 nM [1]
H-Gly-dmP-Glu-OH Drug Info Ki = 3790 nM [7]
AP-7 Drug Info IC50 = 390 nM [4]
4-[3-(4-Phenyl-butylamino)-propyl]-phenol Drug Info IC50 = 20 nM [24]
Nle-Pro-Glu Drug Info Ki = 19500 nM [6]
Ala-Pro-Glu Drug Info Ki = 2660 nM [6]
Gly-Amp-Glu Drug Info Ki = 15540 nM [6]
(D)-Ala-Pro-Glu Drug Info Ki = 5400 nM [6]
Gly-b7Pro-Glu Drug Info Ki = 480 nM [6]
4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol Drug Info IC50 = 8 nM [10]
Phenethyl-(3-phenyl-propyl)-amine Drug Info IC50 = 7300 nM [10]
N,N'-Bis-(4-hexyl-phenyl)-guanidine Drug Info IC50 = 7790 nM [8]
4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol Drug Info IC50 = 35 nM [10]
6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole Drug Info Ki = 5400 nM [17]
ELIPRODIL Drug Info IC50 = 1400 nM [23]
4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol Drug Info IC50 = 300 nM [10]
4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline Drug Info Ki = 29 nM [22]
4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol Drug Info IC50 = 25 nM [23]
4-[2-(4-Phenyl-butylamino)-ethyl]-phenol Drug Info IC50 = 43 nM [10]
2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol Drug Info Ki = 3.2 nM [17]
8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 79 nM [11]
8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 13 nM [11]
3-Hydroxy-1H-benzo[b]azepine-2,5-dione Drug Info IC50 = 830 nM [11]
6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole Drug Info Ki = 8400 nM [17]
4-[2-(3-Phenyl-propylamino)-ethyl]-phenol Drug Info IC50 = 96 nM [10]
4-Benzyl-1-phenethyl-piperidine hydrochloride Drug Info IC50 = 1100 nM [10]
DNQX Drug Info IC50 = 4500 nM [25]
4-Chloro-3-hydroxy-1H-quinolin-2-one Drug Info IC50 = 1400 nM
7-Chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one Drug Info IC50 = 410 nM
L-687414 Drug Info IC50 = 2700 nM
PHENCYCLIDINE Drug Info IC50 = 9.8 nM [26]
Benzyl 4-aminobutyl(3-aminopropyl)carbamate Drug Info IC50 = 17600 nM [27]
4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol Drug Info IC50 = 7700 nM [23]
3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one Drug Info IC50 = 3200 nM
L-698532 Drug Info Ki = 151 nM [5]
5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione Drug Info IC50 = 1300 nM
5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione Drug Info IC50 = 170 nM
6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione Drug Info IC50 = 430 nM [13]
5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione Drug Info IC50 = 280 nM
NBQX Drug Info IC50 = 200 nM [28]
References
REF 1J Med Chem. 1990 Nov;33(11):2944-6.3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
REF 2J Med Chem. 2000 Jun 15;43(12):2371-81.Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity.
REF 3J Med Chem. 1989 Sep;32(9):2171-8.4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity.
REF 4J Med Chem. 1992 Dec 11;35(25):4720-6.Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.
REF 5J Med Chem. 2006 Feb 9;49(3):864-71.Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.
REF 6Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6.New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity.
REF 7Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. Epub 2006 May 2.The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity.
REF 8J Med Chem. 1998 Aug 13;41(17):3298-302.Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents.
REF 9J Med Chem. 1997 Oct 24;40(22):3679-86.5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
REF 10J Med Chem. 1998 Aug 27;41(18):3499-506.Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors.
REF 11J Med Chem. 1996 Nov 8;39(23):4643-53.Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites.
REF 12J Med Chem. 1990 Oct;33(10):2772-7.2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents.
REF 13Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9.3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists.
REF 14J Med Chem. 2005 Feb 24;48(4):995-1018.CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2-carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, a potent selective glycine-site NMDA receptor antagonist.
REF 15J Med Chem. 2005 Apr 7;48(7):2627-37.Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
REF 16Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41. Epub 2005 Oct 5.Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists.
REF 17J Med Chem. 2004 Apr 8;47(8):2089-96.NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
REF 18J Med Chem. 1995 Jun 23;38(13):2483-9.Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists.
REF 19Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
REF 20J Med Chem. 2006 Oct 5;49(20):6015-26.Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies.
REF 21Bioorg Med Chem Lett. 2006 Sep 1;16(17):4638-40. Epub 2006 Jun 16.Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.
REF 22Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.
REF 23J Med Chem. 1999 Jul 29;42(15):2993-3000.4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist.
REF 24Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24.Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-methyl-D-aspartate (NMDA) receptors.
REF 25J Med Chem. 1991 Apr;34(4):1243-52.Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
REF 26J Med Chem. 1996 Nov 22;39(24):4844-52.Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist.
REF 27Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41. Epub 2006 Mar 24.Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents.
REF 28J Med Chem. 2001 Sep 13;44(19):3157-65.Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.